Leucid Bio and Syenex announced a strategic collaboration for in vivo CAR-T cell engineering.
Leucid Bio is a clinical stage biotech company developing next generation CAR-T therapies using a proprietary Lateral CAR platform to improve treatment outcomes for patients with refractory cancers
Leucid Bio is a clinical stage biotech company developing next generation CAR-T therapies using a proprietary Lateral CAR platform to improve treatment outcomes for patients with refractory cancers.